Midostaurin (PKC412)

Catalog No.S8064 Synonyms: CGP 41251

Midostaurin (PKC412) Chemical Structure

Molecular Weight(MW): 570.64

Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.

Size Price Stock Quantity  
USD 110 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.
Targets
PKCα [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
PKCβ1 [1]
(Cell-free assay)
PKCβ2 [1]
(Cell-free assay)
PPK [1]
(Cell-free assay)
22 nM 24 nM 30 nM 31 nM 38 nM
In vitro

Midostaurin(pkc412) is a broad spectrum protein kinase inhibitor. Midostaurin(pkc412) interacts strongly with ATP binding sites of the conventional PKC-α, -β and -γ, PDGFRβ, VEGF-R2, VEGF-R1 and the cyclin-dependant kinase 1-cyclin B complex. Midostaurin(pkc412) inhibits the growth of various human and animal cell lines in vitro at similar submicromolar concentrations. Midostaurin(pkc412) also effectively inhibits the in vitro proliferation of glioblastoma and induced the accumulation of cells in G2/M and formation of giant nuclei with extensive fragmentation and apoptotic bodies. Midostaurin(pkc412) is able to reverse the p-glycoprotein-mediated multidrug resistance of tumor cells in vitro. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MV4-11 cells M{Wzc2N6fG:2b4jpZ4l1gSCjc4PhfS=> MUm3NkBp NGryfHVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOXjRvMUGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOnbHygeIl1\XJvYnz1[UBie3OjeTygTWM2OD1zMjDuUS=> NHvOZW0yQTZ3NESwPC=>
RS4-11 cells NHLv[3VHfW6ldHnvckBie3OjeR?= Mnn2NkBp MVHJcohq[mm2aX;uJI9nKE[OVEOgTXRFKG23dHHueEBifXSxcHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKFKVND2xNUBk\WyuczDh[pRmeiB{IHjyd{BjgSCnbHXjeJJw[2inbXnseY1qdmW|Y3XuZ4Uh[XO|YYmsJGlEPTB;MUOgcm0> NFHCUJQyQTZ3NESwPC=>
CGTH-W-1 cell NGf3coVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4joUmlvcGmkaYTpc44hd2ZiaIXtZY4hS0eWSD3XMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Oi54NTFOwG0> NHXB[GhUSU6JRWK=
SW982 cell M2GyOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV\pWlhzUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ2NjV6IN88US=> NV60SoFMW0GQR1XS
human EoL-1-cell cell NE\rT4NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUfJcohq[mm2aX;uJI9nKGi3bXHuJGVwVC1zLXPlcIwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Oi5yODDuUS=> MoS5V2FPT0WU
MOLM-13 cells Mo\KS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWDV[nFYPzJiaB?= NHLhfnRKdmirYnn0bY9vKG:oIF\MWFMhUVSGIHjleIVzd3q7Z3;1d{BufXSjboSgbY4hcHWvYX6gUW9NVS1zMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEeLNUC9NE4xPTVizszN NHS1V5UzPjB6MUCyNy=>
KASUMI-1 cell MoW0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{XIXmlvcGmkaYTpc44hd2ZiaIXtZY4hU0GVVV3JMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB4MEG2JO69VQ>? MnTVV2FPT0WU
NCI-H1755 cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml2zTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3OVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB4MkezJO69VQ>? M1S4THNCVkeHUh?=
human MES-SA cell NVuyT3J{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NITlO5VKdmirYnn0bY9vKG:oIHj1cYFvKE2HUz3TRUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODd3NESg{txO MlXWV2FPT0WU
human HCC1395 cell NYX5V4I5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVzJcohq[mm2aX;uJI9nKGi3bXHuJGhESzF|OUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA5PDJ6IN88US=> MWnTRW5ITVJ?
human D-336MG cell MkHWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4TodWlvcGmkaYTpc44hd2ZiaIXtZY4hTC1|M{\NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODh5NUSg{txO MYPTRW5ITVJ?
CHP-212 cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWjoOVVDUW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNlEzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yOEe3N{DPxE1? NHzOUnVUSU6JRWK=
human KM12 cell M{PR[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmfXTY5pcWKrdHnvckBw\iCqdX3hckBMVTF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6wPVI4PSEQvF2= M2q1U3NCVkeHUh?=
A204 cell NYD4[XJkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUXkNJlSUW6qaXLpeIlwdiCxZjDoeY1idiCDMkC0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yODB3MjFOwG0> M1zRenNCVkeHUh?=
CAL-51 cell NVTnS3pxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXjJ[|B2UW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjFyN{C5JO69VQ>? NXvHcZdxW0GQR1XS
human A431 cell MlXIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUXJcohq[mm2aX;uJI9nKGi3bXHuJGE1OzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkGxNlE3KM7:TR?= M2HBeXNCVkeHUh?=
NCI-H650 cell NWL4ZmZtT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVvJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNkWwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOTdyODFOwG0> MUXTRW5ITVJ?
A427 cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4HrWWlvcGmkaYTpc44hd2ZiaIXtZY4hSTR{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVE6OThizszN M4HRUnNCVkeHUh?=
human 769-P cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NE\JNGxKdmirYnn0bY9vKG:oIHj1cYFvKDd4OT3QJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOjB6MjFOwG0> Mm\EV2FPT0WU
SW1710 cell NHXXbHhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4j1NmlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOzNzNjFOwG0> M1PNZXNCVkeHUh?=
human H4 cell MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEfWb3FKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xN|k3OyEQvF2= MnHhV2FPT0WU
HT-1080 cell NHTiOGRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoXUTY5pcWKrdHnvckBw\iCqdX3hckBJXC1zMEiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPTl6MjFOwG0> NVjyTGU3W0GQR1XS
human PANC-03-27 cell NUjPZnFKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIfGUmVKdmirYnn0bY9vKG:oIHj1cYFvKFCDTlOtNFMuOjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG2NFIh|ryP MkjYV2FPT0WU
A375 cells M1qyWmN6fG:2b4jpZ4l1gSCjc4PhfS=> Mn6yO|IhcA>? M2fFfnRwgGmlaYT5JIFo[Wmwc4SgbJVu[W5iQUO3OUBk\WyuczDh[pRmeiB5MjDodpMh[nliY3XscEB1cXSncj3icJVmKGG|c3H5MEBKSzVyPUCuNVgh|ryP MVmxPVY2PDRyOB?=
human HOP-62 cell NWW3OHV{TnWwY4Tpc44h[XO|YYm= NIntOFhKdmirYnn0bY9vKG:oIHj1cYFvKEiRUD22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOThyN{Og{txO NHL4W2lUSU6JRWK=
human U031 cell M1TpUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUDJcohq[mm2aX;uJI9nKGi3bXHuJHUxOzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG5Olk5KM7:TR?= MUjTRW5ITVJ?
mouse BAF3 cells MWLQdo9tcW[ncnH0bY9vKGG|c3H5 NVTwcoN3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJJRz[W6|Zn;ycYVlKHerdHigXm5HOTl6LV\HSnIyKGOxboP0dpVkfCxiSVO1NF0xNjJizszN NEPZRWUzOTl|NkW0Ni=>
human G-402 cell MlXKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{nISGlvcGmkaYTpc44hd2ZiaIXtZY4hTy12MEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIxOjV|IN88US=> Mmj1V2FPT0WU
human G-361 cell NWm2[XZbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUjJcohq[mm2aX;uJI9nKGi3bXHuJGcuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNFg2OyEQvF2= NXvYNIZYW0GQR1XS
NCI-H810 cell NEK0To9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlLkTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEixNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjFyMkeg{txO MYnTRW5ITVJ?
NCI-H2030 cell NF7ENHBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV7Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkCzNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjNyME[g{txO MX3TRW5ITVJ?
human HCT-116 cell MmnhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXTJcohq[mm2aX;uJI9nKGi3bXHuJGhEXC1zMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI{PTZ6IN88US=> MULTRW5ITVJ?
human SNU-423 cell NGH2VnRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NF;QZ5FKdmirYnn0bY9vKG:oIHj1cYFvKFOQVT20NlMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ|NkW3JO69VQ>? MknPV2FPT0WU
human SCC-4 cell MkfiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYXJcohq[mm2aX;uJI9nKGi3bXHuJHNESy12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yN|k3PyEQvF2= MnfIV2FPT0WU
human SW48 cell Mn;pS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MULJcohq[mm2aX;uJI9nKGi3bXHuJHNYPDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkK2Olgh|ryP MmWxV2FPT0WU
human SF295 cell M3zZ[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXj2eHcxUW6qaXLpeIlwdiCxZjDoeY1idiCVRkK5OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjd{NUeg{txO MWnTRW5ITVJ?
MDA-MB-231 cell NX[yW3FET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYDEeG5pUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOjNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yPFExOSEQvF2= Ml;hV2FPT0WU
A172 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGHKOG1KdmirYnn0bY9vKG:oIHj1cYFvKEFzN{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlI6OTVizszN M{G5N3NCVkeHUh?=
human BCPAP cell Ml7FS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmL4TY5pcWKrdHnvckBw\iCqdX3hckBDS1CDUDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlk5PzlizszN MoLuV2FPT0WU
human COLO-792 cell MoLDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYGxOW1mUW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVc6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkm5O|Ih|ryP NUnvR4hnW0GQR1XS
human DU-145 cell M1\5fWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXPJcohq[mm2aX;uJI9nKGi3bXHuJGRWNTF2NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|E5QDlizszN MlHNV2FPT0WU
NCI-H2122 cell NHLWfGlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkDCTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKxNlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN{Mki1JO69VQ>? MkX5V2FPT0WU
human SK-UT-1 cell M3[wNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV7Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNVWWLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlMzQTV{IN88US=> MXvTRW5ITVJ?
LXF-289 cell NXvRfXJ5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Moq4TY5pcWKrdHnvckBw\iCqdX3hckBNYEZvMki5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{Ojl4NTFOwG0> NF\VZ29USU6JRWK=
human NCI-H1792 cell MnvnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlXTTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3PVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN|MEm2JO69VQ>? MU\TRW5ITVJ?
MCF7 cell NHexO5FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MULJcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkOzNlc1KM7:TR?= NFXHVHlUSU6JRWK=
HCT-15 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEjrRWhKdmirYnn0bY9vKG:oIHj1cYFvKEiFVD2xOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzN2M{Kg{txO NULsUHhkW0GQR1XS
human NCI-H358 cell NWfOb4JXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUnobXRYUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFM2QCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{O1OVEh|ryP MlrCV2FPT0WU
human HLE cell MlfwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmPRTY5pcWKrdHnvckBw\iCqdX3hckBJVEViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkOzO|UzKM7:TR?= M2nTRnNCVkeHUh?=
human SW1088 cell NFnVeGFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXjJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTB6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|M4QTdizszN NHezRZBUSU6JRWK=
human K5 cell Ml;HS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGnGdY9KdmirYnn0bY9vKG:oIHj1cYFvKEt3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zOlE1QSEQvF2= MX;TRW5ITVJ?
human SR cell NWrrSIR[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWrJcohq[mm2aX;uJI9nKGi3bXHuJHNTKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|NkW3NUDPxE1? NEjhelRUSU6JRWK=
human Calu-3 cell NHvMR5JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlSwTY5pcWKrdHnvckBw\iCqdX3hckBE[Wy3LUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM3QDJ3IN88US=> Mn:zV2FPT0WU
human SK-MEL-30 cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlLoTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytN|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN7OUGzJO69VQ>? M4rieXNCVkeHUh?=
human SW780 cell NWfLcnJmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFTjd5BKdmirYnn0bY9vKG:oIHj1cYFvKFOZN{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41OTF2MjFOwG0> NVXPNGg{W0GQR1XS
NCI-H1563 cell NHvJXI9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUXRXIRPUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE2PjNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkSxOFg1KM7:TR?= NV7UPW1XW0GQR1XS
human MKN45 cell NWm2T2g3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXXWcYpWUW6qaXLpeIlwdiCxZjDoeY1idiCPS160OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDF7M{Gg{txO M3jVdnNCVkeHUh?=
MDA-MB-157 cell M1zvUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmHsTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNVU4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52MkCxOUDPxE1? NITaeoNUSU6JRWK=
human NCI-H522 cell NXP0NW9uT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVTGeWF6UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFUzOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNEKzJO69VQ>? M2TtW3NCVkeHUh?=
human A2780 cell NGXVVWJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mof5TY5pcWKrdHnvckBw\iCqdX3hckBCOjd6MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOFc2ODNizszN MkXaV2FPT0WU
human A498 cell NYTT[mdwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIPOfHlKdmirYnn0bY9vKG:oIHj1cYFvKEF2OUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQ4Pjl|IN88US=> NGjIfoNUSU6JRWK=
human BxPC-3 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEfQVmlKdmirYnn0bY9vKG:oIHj1cYFvKEK6UFOtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDl|Nk[g{txO NHrjVZVUSU6JRWK=
human A2058 cell M33EOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVjJcohq[mm2aX;uJI9nKGi3bXHuJGEzODV6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61Nlg1PCEQvF2= M2jR[nNCVkeHUh?=
human PC-14 cell NVLwcm82T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYj4WHZxUW6qaXLpeIlwdiCxZjDoeY1idiCSQz2xOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTN6NUWg{txO NYTRN3dKW0GQR1XS
human KG-1 cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3O1ZmlvcGmkaYTpc44hd2ZiaIXtZY4hU0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOVU1OTlizszN NG[wOZNUSU6JRWK=
human A375 cell NWTQNm5VT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1H0[WlvcGmkaYTpc44hd2ZiaIXtZY4hSTN5NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOVYyODNizszN MkTKV2FPT0WU
human SW1783 cell Mo\tS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlrmTY5pcWKrdHnvckBw\iCqdX3hckBUXzF5OEOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlc{OzdizszN MnrLV2FPT0WU
human MKN1 cell M4jZc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF7OOHNKdmirYnn0bY9vKG:oIHj1cYFvKE2NTkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg5PDF{IN88US=> Mk[5V2FPT0WU
NCI-H1650 cell NXPiXoNxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3H2OWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOlUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56OEmxOwOBiM7:TR?= M{nE[XNCVkeHUh?=
human HT-1376 cell Mn7PS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVrTdG14UW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xN|c3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC57MkmxPEDPxE1? NVzVU5d1W0GQR1XS
SW872 cell Mm[4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYnJcohq[mm2aX;uJI9nKGi3bXHuJHNYQDd{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD65OFQ2QSEQvF2= NHjiclhUSU6JRWK=
human RT-112 cell M4XKR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUDJcohq[mm2aX;uJI9nKGi3bXHuJHJVNTFzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVc1QDNizszN NWrVVnJVW0GQR1XS
human HT-29 cell NIrwb3lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3z5TWlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk4QTl4IN88US=> NUTQbmdVW0GQR1XS
human U-266 cell M4DqVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1L5O2lvcGmkaYTpc44hd2ZiaIXtZY4hXS1{Nk[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk5OzB{IN88US=> NInD[G9USU6JRWK=
human HEL cell MnewS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGXjSolKdmirYnn0bY9vKG:oIHj1cYFvKEiHTDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVg2OTdizszN NX75[25rW0GQR1XS
human KU812 cell NWLYNXFZT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnqyTY5pcWKrdHnvckBw\iCqdX3hckBMXThzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNVEyPjRizszN NXzoZnBRW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Midostaurin(pkc412) may suppress tumor growth by inhibiting tumor angiogenesis (via its effects on the VEGF receptor tyrosine kinases) in addition to directly inhibiting tumor cell proliferation (via its effects on PKCs). This anti-angiogenic action may contribute to the antimetastatic and broad antitumor activity displayed by midostaurin(pkc412), as well as the synergy with cytotoxic agents, including doxorubicin, cyclophosphamide, cisplatin and gemcitabine. When given orally, the maximally tolerated dose for midostaurin(pkc412) is >300 mg/kg. [1]

Protocol

Cell Research:[2]
+ Expand
  • Cell lines: A549, NCI-H520
  • Concentrations: ~1.0 μM
  • Incubation Time: 24-72 h
  • Method: Each well is added with 5 mM WST-1 and 0.2 mM 1-methoxy PMS and the absorbance at 450 nm is measured by a Microplate Reader.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Colo 205 colorectal tumors xenograft
  • Formulation: sterile water
  • Dosages: 50 mg/kg, 200 mg/kg, once daily
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (175.24 mM)
Ethanol 20 mg/mL warmed (35.04 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.
4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 570.64
Formula

C35H30N4O4

CAS No. 120685-11-2
Storage powder
in solvent
Synonyms CGP 41251

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01429337 Recruiting Hepatic Impairment Novartis Pharmaceuticals|Novartis March 7 2011 Phase 1
NCT03280030 Recruiting Acute Myeloid Leukemia Novartis Pharmaceuticals|Novartis April 6 2018 Phase 2
NCT02756962 Recruiting Acute Myeloid Leukemia Washington University School of Medicine|The Leukemia and Lymphoma Society July 6 2016 Phase 2
NCT01883362 Completed Acute Myeloid Leukemia Novartis Pharmaceuticals|Novartis February 6 2014 Phase 2
NCT02634827 Active not recruiting Acute Myeloid Leukemia With FLT3/ITD Mutation|Acute Myeloid Leukemia With Gene Mutations|FLT3 Tyrosine Kinase Domain Point Mutation|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia Mayo Clinic|National Cancer Institute (NCI) December 30 2015 Phase 2
NCT00045942 Completed Acute Myeloid Leukemia|Myelodysplastic Syndromes Novartis Pharmaceuticals|Novartis January 30 2002 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products

Tags: buy Midostaurin (PKC412) | Midostaurin (PKC412) supplier | purchase Midostaurin (PKC412) | Midostaurin (PKC412) cost | Midostaurin (PKC412) manufacturer | order Midostaurin (PKC412) | Midostaurin (PKC412) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID